View ValuationCrestchem 将来の成長Future 基準チェック /06現在、 Crestchemの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長19.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 18Crestchem Limited to Report Q4, 2026 Results on May 26, 2026Crestchem Limited announced that they will report Q4, 2026 results on May 26, 2026Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹119, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 18% over the past three years.New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$10m (₹233.3m market cap, or US$2.49m). Minor Risk Revenue is less than US$5m (₹266m revenue, or US$2.8m).Recent Insider Transactions • Feb 27Chairman & MD recently bought ₹69k worth of stockOn the 23rd of February, Dipak Patel bought around 750 shares on-market at roughly ₹91.45 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹80k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹533k worth in shares.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.39 (vs ₹1.74 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.39 (up from ₹1.74 in 3Q 2025). Revenue: ₹73.4m (up 53% from 3Q 2025). Net income: ₹7.17m (up 38% from 3Q 2025). Profit margin: 9.8% (down from 11% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹95.46, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 49% over the past three years.お知らせ • Feb 07Crestchem Limited to Report Q3, 2026 Results on Feb 13, 2026Crestchem Limited announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Feb 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹269.3m market cap, or US$2.98m). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (8.3% net profit margin). Revenue is less than US$5m (₹243m revenue, or US$2.7m).Reported Earnings • Nov 14Second quarter 2026 earnings releasedSecond quarter 2026 results: Revenue: ₹73.4m (down 6.0% from 2Q 2025). Net income: ₹5.45m (down 45% from 2Q 2025). Profit margin: 7.4% (down from 13% in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 04Crestchem Limited to Report First Half, 2026 Results on Nov 12, 2025Crestchem Limited announced that they will report first half, 2026 results on Nov 12, 2025お知らせ • Aug 06Crestchem Limited to Report Q1, 2026 Results on Aug 12, 2025Crestchem Limited announced that they will report Q1, 2026 results on Aug 12, 2025Reported Earnings • Jul 31Full year 2025 earnings released: EPS: ₹9.09 (vs ₹7.15 in FY 2024)Full year 2025 results: EPS: ₹9.09 (up from ₹7.15 in FY 2024). Revenue: ₹250.8m (up 18% from FY 2024). Net income: ₹27.3m (up 27% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 59% per year.Board Change • Jul 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Chairman & MD Dipak Patel is the most experienced director on the board, commencing their role in 2008. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 23+ 1 more updateCrestchem Limited Announces Resignation of Khyati Vyas as CFO, Effective July 1, 2025Crestchem Limited announced the resignation of Khyati Vyas as CFO with effect from July 01, 2025, due to her health problems.お知らせ • Jun 24Crestchem Limited, Annual General Meeting, Aug 21, 2025Crestchem Limited, Annual General Meeting, Aug 21, 2025, at 12:15 Indian Standard Time.Reported Earnings • May 29Full year 2025 earnings released: EPS: ₹9.09 (vs ₹7.15 in FY 2024)Full year 2025 results: EPS: ₹9.09 (up from ₹7.15 in FY 2024). Revenue: ₹255.2m (up 20% from FY 2024). Net income: ₹27.3m (up 27% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 58% per year.お知らせ • May 28Crestchem Limited Recommends Final Dividend for the Financial Year Ended March 31, 2025Crestchem Limited recommended a final dividend at INR 1.00 (10%) per equity share of face value of INR 10 each for the financial year ended March 31, 2025. The said final dividend, if approved by the members of the Company at the upcoming Annual General Meeting (`AGM') of the Company, will be paid/dispatched within stipulated time period of its declaration at the said AGM of the Company.お知らせ • May 20Crestchem Limited to Report Q4, 2025 Results on May 28, 2025Crestchem Limited announced that they will report Q4, 2025 results on May 28, 2025Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹223, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 433% over the past three years.Recent Insider Transactions • Mar 23Chairman & MD recently bought ₹80k worth of stockOn the 21st of March, Dipak Patel bought around 350 shares on-market at roughly ₹230 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹829k worth in shares.Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹216, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 441% over the past three years.Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹1.74 (vs ₹3.03 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.74 (down from ₹3.03 in 3Q 2024). Revenue: ₹48.0m (down 35% from 3Q 2024). Net income: ₹5.21m (down 43% from 3Q 2024). Profit margin: 11% (down from 12% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹306, the stock trades at a trailing P/E ratio of 29x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 636% over the past three years.お知らせ • Feb 04Crestchem Limited to Report Q3, 2025 Results on Feb 12, 2025Crestchem Limited announced that they will report Q3, 2025 results on Feb 12, 2025Recent Insider Transactions • Jan 02Chairman & MD recently bought ₹61k worth of stockOn the 27th of December, Dipak Patel bought around 250 shares on-market at roughly ₹244 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹176k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹742k worth in shares.Valuation Update With 7 Day Price Move • Jan 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹294, the stock trades at a trailing P/E ratio of 35.2x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 560% over the past three years.Valuation Update With 7 Day Price Move • Nov 18Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹264, the stock trades at a trailing P/E ratio of 31.6x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 476% over the past three years.お知らせ • Oct 31Crestchem Limited to Report Q2, 2025 Results on Nov 12, 2024Crestchem Limited announced that they will report Q2, 2025 results on Nov 12, 2024Valuation Update With 7 Day Price Move • Oct 25Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹226, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 508% over the past three years.Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₹249, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 438% over the past three years.Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹190, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 257% over the past three years.お知らせ • Sep 12Crestchem Limited Announces Resignation of Binaben Parasbhai Patel as Independent Director, Effective September 20, 2024Crestchem Limited announced resignation of Smt. Binaben Parasbhai Patel as Independent Director, w.e.f. September 20, 2024.Reported Earnings • Aug 07Full year 2024 earnings released: EPS: ₹7.15 (vs ₹2.31 in FY 2023)Full year 2024 results: EPS: ₹7.15 (up from ₹2.31 in FY 2023). Revenue: ₹212.6m (up 27% from FY 2023). Net income: ₹21.5m (up 210% from FY 2023). Profit margin: 10% (up from 4.1% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 07Crestchem Limited to Report Q1, 2025 Results on Aug 12, 2024Crestchem Limited announced that they will report Q1, 2025 results at 12:15 PM, Indian Standard Time on Aug 12, 2024Board Change • Jul 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Nitinkumar Shah was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹144, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 161% over the past three years.お知らせ • Jul 05Crestchem Limited Announces Director ChangesCrestchem Limited at its board meeting held on July 4, 2024 announced appointment of Smt. Priyanka M. Patel as additional director effective from July 4, 2024. Further, the company announced Resignation of Shri Manojkumar B. Patel as Independent Director effective from July 04, 2024, Due to his preoccupations. And Shri Rajesh I Mody ceased to be Independent Director effective from July 4, 2024 as his tenure as Independent director is over.お知らせ • Jul 01Crestchem Limited, Annual General Meeting, Aug 30, 2024Crestchem Limited, Annual General Meeting, Aug 30, 2024.Recent Insider Transactions • Jun 25Chairman & MD recently bought ₹53k worth of stockOn the 22nd of June, Dipak Patel bought around 388 shares on-market at roughly ₹136 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹300k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹811k worth in shares.Recent Insider Transactions • Jun 08Chairman & MD recently bought ₹300k worth of stockOn the 3rd of June, Dipak Patel bought around 2k shares on-market at roughly ₹143 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹758k worth in shares.お知らせ • May 30Crestchem Limited Recommends Final Maiden Dividend for the Financial Year Ended March 31, 2024Crestchem Limited at its Board meeting held on May 28, 2024, recommended a final maiden dividend at INR 0.50 (5%) per equity share of face value of INR 10 each for the financial year ended March 31, 2024. The final dividend, if approved by the members of the company at the upcoming Annual General Meeting of the Company, will be paid/dispatched within stipulated time period of its declaration at the said AGM of the Company.Reported Earnings • May 30Full year 2024 earnings released: EPS: ₹7.15 (vs ₹2.31 in FY 2023)Full year 2024 results: EPS: ₹7.15 (up from ₹2.31 in FY 2023). Revenue: ₹215.2m (up 29% from FY 2023). Net income: ₹21.5m (up 210% from FY 2023). Profit margin: 10.0% (up from 4.1% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 22Crestchem Limited to Report Q4, 2024 Results on May 28, 2024Crestchem Limited announced that they will report Q4, 2024 results on May 28, 2024Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹105, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 277% over the past three years.Reported Earnings • Feb 14Third quarter 2024 earnings released: EPS: ₹3.03 (vs ₹0.72 in 3Q 2023)Third quarter 2024 results: EPS: ₹3.03 (up from ₹0.72 in 3Q 2023). Revenue: ₹74.2m (up 85% from 3Q 2023). Net income: ₹9.09m (up 322% from 3Q 2023). Profit margin: 12% (up from 5.4% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹80.60, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 28% over the past three years.Reported Earnings • Nov 05Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: ₹45.5m (up 17% from 2Q 2023). Net income: ₹3.39m (up 176% from 2Q 2023). Profit margin: 7.5% (up from 3.2% in 2Q 2023). The increase in margin was driven by higher revenue.お知らせ • Oct 28Crestchem Limited to Report Q2, 2024 Results on Nov 04, 2023Crestchem Limited announced that they will report Q2, 2024 results on Nov 04, 2023Recent Insider Transactions • Sep 24Chairman & MD recently bought ₹111k worth of stockOn the 22nd of September, Dipak Patel bought around 2k shares on-market at roughly ₹62.47 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹116k. Despite this recent buy, Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹152k.お知らせ • Aug 05Crestchem Limited to Report Q1, 2024 Results on Aug 12, 2023Crestchem Limited announced that they will report Q1, 2024 results on Aug 12, 2023Reported Earnings • Jul 30Full year 2023 earnings released: EPS: ₹2.31 (vs ₹1.89 in FY 2022)Full year 2023 results: EPS: ₹2.31 (up from ₹1.89 in FY 2022). Revenue: ₹168.8m (up 112% from FY 2022). Net income: ₹6.93m (up 22% from FY 2022). Profit margin: 4.1% (down from 7.1% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 83% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 07Crestchem Limited, Annual General Meeting, Aug 24, 2023Crestchem Limited, Annual General Meeting, Aug 24, 2023, at 12:15 Indian Standard Time.Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹88.04, the stock trades at a trailing P/E ratio of 35.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 91% over the past year.Valuation Update With 7 Day Price Move • May 18Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹80.65, the stock trades at a trailing P/E ratio of 32.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 95% over the past year.Valuation Update With 7 Day Price Move • Apr 19Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹101, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 863% over the past three years.Recent Insider Transactions • Mar 23Chairman & MD recently sold ₹226k worth of stockOn the 21st of March, Dipak Patel sold around 2k shares on-market at roughly ₹98.48 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹378k.Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹112, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 917% over the past three years.Recent Insider Transactions • Mar 13Chairman & MD recently sold ₹166k worth of stockOn the 10th of March, Dipak Patel sold around 2k shares on-market at roughly ₹91.88 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹152k.Valuation Update With 7 Day Price Move • Mar 08Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹83.83, the stock trades at a trailing P/E ratio of 33.5x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 629% over the past three years.Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹74.95, the stock trades at a trailing P/E ratio of 29.9x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 552% over the past three years.お知らせ • Jan 31Crestchem Limited to Report Q3, 2023 Results on Feb 11, 2023Crestchem Limited announced that they will report Q3, 2023 results on Feb 11, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹0.41 (vs ₹0.15 loss in 2Q 2022)Second quarter 2023 results: EPS: ₹0.41 (up from ₹0.15 loss in 2Q 2022). Revenue: ₹39.2m (up ₹39.1m from 2Q 2022). Net income: ₹1.23m (up ₹1.67m from 2Q 2022). Profit margin: 3.1% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Nov 05Crestchem Limited to Report Q2, 2023 Results on Nov 12, 2022Crestchem Limited announced that they will report Q2, 2023 results on Nov 12, 2022Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹81.10, the stock trades at a trailing P/E ratio of 41.7x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 479% over the past three years.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹52.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 257% over the past three years.Buying Opportunity • Aug 30Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be ₹51.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Meanwhile, the company has become profitable.Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹43.45, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 18x in the Chemicals industry in India. Total loss to shareholders of 15% over the past year.Buying Opportunity • Aug 10Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.9%. The fair value is estimated to be ₹51.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Meanwhile, the company has become profitable.Reported Earnings • Aug 02Full year 2022 earnings released: EPS: ₹1.89 (vs ₹1.91 in FY 2021)Full year 2022 results: EPS: ₹1.89 (down from ₹1.91 in FY 2021). Revenue: ₹79.5m (up 4.0% from FY 2021). Net income: ₹5.67m (down 1.2% from FY 2021). Profit margin: 7.1% (down from 7.5% in FY 2021). The decrease in margin was driven by higher expenses.お知らせ • Jul 29Crestchem Limited, Annual General Meeting, Aug 25, 2022Crestchem Limited, Annual General Meeting, Aug 25, 2022, at 12:15 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Accounts of the Company for the period (12 months) ended on 31st March 2022, and the Director's and Auditor's Reports thereon; to consider and, if thought fit, to pass with or without modification, the following Resolution as an Ordinary Resolution; and to consider any other business matters.Valuation Update With 7 Day Price Move • Jul 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹46.80, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 234% over the past three years.Reported Earnings • Jun 01Full year 2022 earnings released: EPS: ₹1.89 (vs ₹1.91 in FY 2021)Full year 2022 results: EPS: ₹1.89 (down from ₹1.91 in FY 2021). Revenue: ₹80.2m (up 5.0% from FY 2021). Net income: ₹5.67m (down 1.2% from FY 2021). Profit margin: 7.1% (down from 7.5% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 24Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹47.00, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 201% over the past three years.Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹50.00, the stock trades at a trailing P/E ratio of 26.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 251% over the past three years.Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.72 (up from ₹0.18 in 3Q 2021). Revenue: ₹26.9m (up 123% from 3Q 2021). Net income: ₹2.15m (up 293% from 3Q 2021). Profit margin: 8.0% (up from 4.6% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Dec 14Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹39.05, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 18x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.Valuation Update With 7 Day Price Move • Nov 29Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹38.00, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 17x in the Chemicals industry in India. Total loss to shareholders of 42% over the past year.Reported Earnings • Oct 28Second quarter 2022 earnings released: ₹0.15 loss per share (vs ₹0.68 profit in 2Q 2021)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹217.0k (down 99% from 2Q 2021). Net loss: ₹446.0k (down 122% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Oct 26Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹39.40, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 243% over the past three years.Board Change • Sep 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Valuation Update With 7 Day Price Move • Aug 24Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹51.00, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 16x in the Chemicals industry in India. Total returns to shareholders of 343% over the past three years.Valuation Update With 7 Day Price Move • Jul 20Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹47.30, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 294% over the past three years.Reported Earnings • Jun 27Full year 2021 earnings released: EPS ₹1.91 (vs ₹1.48 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹76.4m (up 23% from FY 2020). Net income: ₹5.74m (up 29% from FY 2020). Profit margin: 7.5% (up from 7.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹41.10, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 242% over the past three years.Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹38.15, the stock trades at a trailing P/E ratio of 23.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 218% over the past three years.Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹30.20, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 140% over the past three years.Is New 90 Day High Low • Mar 16New 90-day low: ₹26.95The company is down 43% from a price of ₹46.90 on 16 December 2020. Underperformed the Indian market, which is up 13% over the last 90 days. Lagged the Chemicals industry, which is up 8.0% over the same period.Valuation Update With 7 Day Price Move • Feb 12Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹28.60, the stock is trading at a trailing P/E ratio of 13.7x, down from the previous P/E ratio of 16.7x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 129%.お知らせ • Feb 05Crestchem Limited to Report Q3, 2021 Results on Feb 10, 2021Crestchem Limited announced that they will report Q3, 2021 results on Feb 10, 2021Is New 90 Day High Low • Feb 02New 90-day low: ₹33.95The company is down 33% from its price of ₹51.05 on 04 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.Is New 90 Day High Low • Jan 17New 90-day low: ₹42.15The company is down 1.0% from its price of ₹42.50 on 19 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Crestchem は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:526269 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202526622N/AN/AN/A9/30/2025243205859N/A6/30/202524925N/AN/AN/A3/31/2025251271416N/A12/31/202423528N/AN/AN/A9/30/20242603255N/A6/30/202422725N/AN/AN/A3/31/20242132123N/A12/31/202318516N/AN/AN/A9/30/2023163102223N/A6/30/20231578N/AN/AN/A3/31/202316772222N/A12/31/20221769N/AN/AN/A9/30/202215181414N/A6/30/20221136N/AN/AN/A3/31/202279688N/A12/31/2021676N/AN/AN/A9/30/202152433N/A6/30/2021767N/AN/AN/A3/31/202176634N/A12/31/2020755N/AN/AN/A9/30/2020856N/AN/AN/A6/30/2020756N/AN/AN/A3/31/202062433N/A12/31/2019392N/AN/AN/A9/30/2019160N/AN/AN/A6/30/20192-2N/AN/AN/A3/31/20191-2N/A0N/A12/31/20180-2N/AN/AN/A9/30/20180-2N/AN/AN/A6/30/20180-2N/AN/AN/A3/31/20181-2N/A-7N/A12/31/20171-2N/AN/AN/A9/30/20171-2N/AN/AN/A6/30/20171-2N/AN/AN/A3/31/20171-2N/A0N/A12/31/20161-1N/AN/AN/A9/30/20161-1N/AN/AN/A6/30/201600N/AN/AN/A3/31/201611N/A-3N/A12/31/201500N/AN/AN/A9/30/201508N/AN/AN/A6/30/201508N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 526269の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 526269の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 526269の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 526269の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 526269の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 526269の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 11:20終値2026/05/21 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Crestchem Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 18Crestchem Limited to Report Q4, 2026 Results on May 26, 2026Crestchem Limited announced that they will report Q4, 2026 results on May 26, 2026
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹119, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 18% over the past three years.
New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$10m (₹233.3m market cap, or US$2.49m). Minor Risk Revenue is less than US$5m (₹266m revenue, or US$2.8m).
Recent Insider Transactions • Feb 27Chairman & MD recently bought ₹69k worth of stockOn the 23rd of February, Dipak Patel bought around 750 shares on-market at roughly ₹91.45 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹80k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹533k worth in shares.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.39 (vs ₹1.74 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.39 (up from ₹1.74 in 3Q 2025). Revenue: ₹73.4m (up 53% from 3Q 2025). Net income: ₹7.17m (up 38% from 3Q 2025). Profit margin: 9.8% (down from 11% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹95.46, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 49% over the past three years.
お知らせ • Feb 07Crestchem Limited to Report Q3, 2026 Results on Feb 13, 2026Crestchem Limited announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Feb 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹269.3m market cap, or US$2.98m). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (8.3% net profit margin). Revenue is less than US$5m (₹243m revenue, or US$2.7m).
Reported Earnings • Nov 14Second quarter 2026 earnings releasedSecond quarter 2026 results: Revenue: ₹73.4m (down 6.0% from 2Q 2025). Net income: ₹5.45m (down 45% from 2Q 2025). Profit margin: 7.4% (down from 13% in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 04Crestchem Limited to Report First Half, 2026 Results on Nov 12, 2025Crestchem Limited announced that they will report first half, 2026 results on Nov 12, 2025
お知らせ • Aug 06Crestchem Limited to Report Q1, 2026 Results on Aug 12, 2025Crestchem Limited announced that they will report Q1, 2026 results on Aug 12, 2025
Reported Earnings • Jul 31Full year 2025 earnings released: EPS: ₹9.09 (vs ₹7.15 in FY 2024)Full year 2025 results: EPS: ₹9.09 (up from ₹7.15 in FY 2024). Revenue: ₹250.8m (up 18% from FY 2024). Net income: ₹27.3m (up 27% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 59% per year.
Board Change • Jul 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Chairman & MD Dipak Patel is the most experienced director on the board, commencing their role in 2008. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 23+ 1 more updateCrestchem Limited Announces Resignation of Khyati Vyas as CFO, Effective July 1, 2025Crestchem Limited announced the resignation of Khyati Vyas as CFO with effect from July 01, 2025, due to her health problems.
お知らせ • Jun 24Crestchem Limited, Annual General Meeting, Aug 21, 2025Crestchem Limited, Annual General Meeting, Aug 21, 2025, at 12:15 Indian Standard Time.
Reported Earnings • May 29Full year 2025 earnings released: EPS: ₹9.09 (vs ₹7.15 in FY 2024)Full year 2025 results: EPS: ₹9.09 (up from ₹7.15 in FY 2024). Revenue: ₹255.2m (up 20% from FY 2024). Net income: ₹27.3m (up 27% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 58% per year.
お知らせ • May 28Crestchem Limited Recommends Final Dividend for the Financial Year Ended March 31, 2025Crestchem Limited recommended a final dividend at INR 1.00 (10%) per equity share of face value of INR 10 each for the financial year ended March 31, 2025. The said final dividend, if approved by the members of the Company at the upcoming Annual General Meeting (`AGM') of the Company, will be paid/dispatched within stipulated time period of its declaration at the said AGM of the Company.
お知らせ • May 20Crestchem Limited to Report Q4, 2025 Results on May 28, 2025Crestchem Limited announced that they will report Q4, 2025 results on May 28, 2025
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹223, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 433% over the past three years.
Recent Insider Transactions • Mar 23Chairman & MD recently bought ₹80k worth of stockOn the 21st of March, Dipak Patel bought around 350 shares on-market at roughly ₹230 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹829k worth in shares.
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹216, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 441% over the past three years.
Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹1.74 (vs ₹3.03 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.74 (down from ₹3.03 in 3Q 2024). Revenue: ₹48.0m (down 35% from 3Q 2024). Net income: ₹5.21m (down 43% from 3Q 2024). Profit margin: 11% (down from 12% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹306, the stock trades at a trailing P/E ratio of 29x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 636% over the past three years.
お知らせ • Feb 04Crestchem Limited to Report Q3, 2025 Results on Feb 12, 2025Crestchem Limited announced that they will report Q3, 2025 results on Feb 12, 2025
Recent Insider Transactions • Jan 02Chairman & MD recently bought ₹61k worth of stockOn the 27th of December, Dipak Patel bought around 250 shares on-market at roughly ₹244 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹176k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹742k worth in shares.
Valuation Update With 7 Day Price Move • Jan 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹294, the stock trades at a trailing P/E ratio of 35.2x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 560% over the past three years.
Valuation Update With 7 Day Price Move • Nov 18Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹264, the stock trades at a trailing P/E ratio of 31.6x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 476% over the past three years.
お知らせ • Oct 31Crestchem Limited to Report Q2, 2025 Results on Nov 12, 2024Crestchem Limited announced that they will report Q2, 2025 results on Nov 12, 2024
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹226, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 508% over the past three years.
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₹249, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 438% over the past three years.
Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹190, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 257% over the past three years.
お知らせ • Sep 12Crestchem Limited Announces Resignation of Binaben Parasbhai Patel as Independent Director, Effective September 20, 2024Crestchem Limited announced resignation of Smt. Binaben Parasbhai Patel as Independent Director, w.e.f. September 20, 2024.
Reported Earnings • Aug 07Full year 2024 earnings released: EPS: ₹7.15 (vs ₹2.31 in FY 2023)Full year 2024 results: EPS: ₹7.15 (up from ₹2.31 in FY 2023). Revenue: ₹212.6m (up 27% from FY 2023). Net income: ₹21.5m (up 210% from FY 2023). Profit margin: 10% (up from 4.1% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 07Crestchem Limited to Report Q1, 2025 Results on Aug 12, 2024Crestchem Limited announced that they will report Q1, 2025 results at 12:15 PM, Indian Standard Time on Aug 12, 2024
Board Change • Jul 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Nitinkumar Shah was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹144, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 161% over the past three years.
お知らせ • Jul 05Crestchem Limited Announces Director ChangesCrestchem Limited at its board meeting held on July 4, 2024 announced appointment of Smt. Priyanka M. Patel as additional director effective from July 4, 2024. Further, the company announced Resignation of Shri Manojkumar B. Patel as Independent Director effective from July 04, 2024, Due to his preoccupations. And Shri Rajesh I Mody ceased to be Independent Director effective from July 4, 2024 as his tenure as Independent director is over.
お知らせ • Jul 01Crestchem Limited, Annual General Meeting, Aug 30, 2024Crestchem Limited, Annual General Meeting, Aug 30, 2024.
Recent Insider Transactions • Jun 25Chairman & MD recently bought ₹53k worth of stockOn the 22nd of June, Dipak Patel bought around 388 shares on-market at roughly ₹136 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹300k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹811k worth in shares.
Recent Insider Transactions • Jun 08Chairman & MD recently bought ₹300k worth of stockOn the 3rd of June, Dipak Patel bought around 2k shares on-market at roughly ₹143 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹758k worth in shares.
お知らせ • May 30Crestchem Limited Recommends Final Maiden Dividend for the Financial Year Ended March 31, 2024Crestchem Limited at its Board meeting held on May 28, 2024, recommended a final maiden dividend at INR 0.50 (5%) per equity share of face value of INR 10 each for the financial year ended March 31, 2024. The final dividend, if approved by the members of the company at the upcoming Annual General Meeting of the Company, will be paid/dispatched within stipulated time period of its declaration at the said AGM of the Company.
Reported Earnings • May 30Full year 2024 earnings released: EPS: ₹7.15 (vs ₹2.31 in FY 2023)Full year 2024 results: EPS: ₹7.15 (up from ₹2.31 in FY 2023). Revenue: ₹215.2m (up 29% from FY 2023). Net income: ₹21.5m (up 210% from FY 2023). Profit margin: 10.0% (up from 4.1% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 22Crestchem Limited to Report Q4, 2024 Results on May 28, 2024Crestchem Limited announced that they will report Q4, 2024 results on May 28, 2024
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹105, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 277% over the past three years.
Reported Earnings • Feb 14Third quarter 2024 earnings released: EPS: ₹3.03 (vs ₹0.72 in 3Q 2023)Third quarter 2024 results: EPS: ₹3.03 (up from ₹0.72 in 3Q 2023). Revenue: ₹74.2m (up 85% from 3Q 2023). Net income: ₹9.09m (up 322% from 3Q 2023). Profit margin: 12% (up from 5.4% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹80.60, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 28% over the past three years.
Reported Earnings • Nov 05Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: ₹45.5m (up 17% from 2Q 2023). Net income: ₹3.39m (up 176% from 2Q 2023). Profit margin: 7.5% (up from 3.2% in 2Q 2023). The increase in margin was driven by higher revenue.
お知らせ • Oct 28Crestchem Limited to Report Q2, 2024 Results on Nov 04, 2023Crestchem Limited announced that they will report Q2, 2024 results on Nov 04, 2023
Recent Insider Transactions • Sep 24Chairman & MD recently bought ₹111k worth of stockOn the 22nd of September, Dipak Patel bought around 2k shares on-market at roughly ₹62.47 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹116k. Despite this recent buy, Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹152k.
お知らせ • Aug 05Crestchem Limited to Report Q1, 2024 Results on Aug 12, 2023Crestchem Limited announced that they will report Q1, 2024 results on Aug 12, 2023
Reported Earnings • Jul 30Full year 2023 earnings released: EPS: ₹2.31 (vs ₹1.89 in FY 2022)Full year 2023 results: EPS: ₹2.31 (up from ₹1.89 in FY 2022). Revenue: ₹168.8m (up 112% from FY 2022). Net income: ₹6.93m (up 22% from FY 2022). Profit margin: 4.1% (down from 7.1% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 83% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 07Crestchem Limited, Annual General Meeting, Aug 24, 2023Crestchem Limited, Annual General Meeting, Aug 24, 2023, at 12:15 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹88.04, the stock trades at a trailing P/E ratio of 35.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 91% over the past year.
Valuation Update With 7 Day Price Move • May 18Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹80.65, the stock trades at a trailing P/E ratio of 32.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 95% over the past year.
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹101, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 863% over the past three years.
Recent Insider Transactions • Mar 23Chairman & MD recently sold ₹226k worth of stockOn the 21st of March, Dipak Patel sold around 2k shares on-market at roughly ₹98.48 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹378k.
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹112, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 917% over the past three years.
Recent Insider Transactions • Mar 13Chairman & MD recently sold ₹166k worth of stockOn the 10th of March, Dipak Patel sold around 2k shares on-market at roughly ₹91.88 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹152k.
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹83.83, the stock trades at a trailing P/E ratio of 33.5x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 629% over the past three years.
Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹74.95, the stock trades at a trailing P/E ratio of 29.9x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 552% over the past three years.
お知らせ • Jan 31Crestchem Limited to Report Q3, 2023 Results on Feb 11, 2023Crestchem Limited announced that they will report Q3, 2023 results on Feb 11, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹0.41 (vs ₹0.15 loss in 2Q 2022)Second quarter 2023 results: EPS: ₹0.41 (up from ₹0.15 loss in 2Q 2022). Revenue: ₹39.2m (up ₹39.1m from 2Q 2022). Net income: ₹1.23m (up ₹1.67m from 2Q 2022). Profit margin: 3.1% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Nov 05Crestchem Limited to Report Q2, 2023 Results on Nov 12, 2022Crestchem Limited announced that they will report Q2, 2023 results on Nov 12, 2022
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹81.10, the stock trades at a trailing P/E ratio of 41.7x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 479% over the past three years.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹52.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 257% over the past three years.
Buying Opportunity • Aug 30Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be ₹51.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Meanwhile, the company has become profitable.
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹43.45, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 18x in the Chemicals industry in India. Total loss to shareholders of 15% over the past year.
Buying Opportunity • Aug 10Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.9%. The fair value is estimated to be ₹51.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Meanwhile, the company has become profitable.
Reported Earnings • Aug 02Full year 2022 earnings released: EPS: ₹1.89 (vs ₹1.91 in FY 2021)Full year 2022 results: EPS: ₹1.89 (down from ₹1.91 in FY 2021). Revenue: ₹79.5m (up 4.0% from FY 2021). Net income: ₹5.67m (down 1.2% from FY 2021). Profit margin: 7.1% (down from 7.5% in FY 2021). The decrease in margin was driven by higher expenses.
お知らせ • Jul 29Crestchem Limited, Annual General Meeting, Aug 25, 2022Crestchem Limited, Annual General Meeting, Aug 25, 2022, at 12:15 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Accounts of the Company for the period (12 months) ended on 31st March 2022, and the Director's and Auditor's Reports thereon; to consider and, if thought fit, to pass with or without modification, the following Resolution as an Ordinary Resolution; and to consider any other business matters.
Valuation Update With 7 Day Price Move • Jul 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹46.80, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 234% over the past three years.
Reported Earnings • Jun 01Full year 2022 earnings released: EPS: ₹1.89 (vs ₹1.91 in FY 2021)Full year 2022 results: EPS: ₹1.89 (down from ₹1.91 in FY 2021). Revenue: ₹80.2m (up 5.0% from FY 2021). Net income: ₹5.67m (down 1.2% from FY 2021). Profit margin: 7.1% (down from 7.5% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 24Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹47.00, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 201% over the past three years.
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹50.00, the stock trades at a trailing P/E ratio of 26.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 251% over the past three years.
Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.72 (up from ₹0.18 in 3Q 2021). Revenue: ₹26.9m (up 123% from 3Q 2021). Net income: ₹2.15m (up 293% from 3Q 2021). Profit margin: 8.0% (up from 4.6% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Dec 14Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹39.05, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 18x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.
Valuation Update With 7 Day Price Move • Nov 29Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹38.00, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 17x in the Chemicals industry in India. Total loss to shareholders of 42% over the past year.
Reported Earnings • Oct 28Second quarter 2022 earnings released: ₹0.15 loss per share (vs ₹0.68 profit in 2Q 2021)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹217.0k (down 99% from 2Q 2021). Net loss: ₹446.0k (down 122% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Oct 26Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹39.40, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 243% over the past three years.
Board Change • Sep 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Aug 24Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹51.00, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 16x in the Chemicals industry in India. Total returns to shareholders of 343% over the past three years.
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹47.30, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 294% over the past three years.
Reported Earnings • Jun 27Full year 2021 earnings released: EPS ₹1.91 (vs ₹1.48 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹76.4m (up 23% from FY 2020). Net income: ₹5.74m (up 29% from FY 2020). Profit margin: 7.5% (up from 7.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹41.10, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 242% over the past three years.
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹38.15, the stock trades at a trailing P/E ratio of 23.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 218% over the past three years.
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹30.20, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 140% over the past three years.
Is New 90 Day High Low • Mar 16New 90-day low: ₹26.95The company is down 43% from a price of ₹46.90 on 16 December 2020. Underperformed the Indian market, which is up 13% over the last 90 days. Lagged the Chemicals industry, which is up 8.0% over the same period.
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹28.60, the stock is trading at a trailing P/E ratio of 13.7x, down from the previous P/E ratio of 16.7x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 129%.
お知らせ • Feb 05Crestchem Limited to Report Q3, 2021 Results on Feb 10, 2021Crestchem Limited announced that they will report Q3, 2021 results on Feb 10, 2021
Is New 90 Day High Low • Feb 02New 90-day low: ₹33.95The company is down 33% from its price of ₹51.05 on 04 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.
Is New 90 Day High Low • Jan 17New 90-day low: ₹42.15The company is down 1.0% from its price of ₹42.50 on 19 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.